Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.

Ann Oncol · 2017 · PMC5834015 · PMID 28453615

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

For everolimus plus exemestane in breast cancer, the 4.4 months difference in OS was not significant although the PFS difference of 4.6 months was highly significant albeit in the setting of excessive censoring in the everolimus arm due to toxicity [ 28 , 62 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.